Moleculera Labs provides next-generation antibody tests that detect whether an autoimmune reaction is causing neurologic or psychiatric symptoms. The company is dedicated to improving the lives of children and adults impacted by infection-induced autoimmune diseases affecting the brain.
The Cunningham Panel™ assists physicians in diagnosing autoimmune neurologic and psychiatric disorders, including PANS and PANDAS.
Moleculera Labs is the sole provider of a testing panel which assists physicians in their diagnosis of autoimmune neuropsychiatric disorders, such as PANS and PANDAS. The Cunningham Panel™ is the first and only test of its kind in the world, and is the result of more than a decade of research and development.
LEADERS IN SPECIALIZED TESTING FOR AUTOIMMUNE NEUROLOGIC DISORDERS
Moleculera Labs – fully-certified and fully-accredited clinical laboratory
Moleculera Labs is a fully-certified and fully-accredited clinical laboratory registered with CLIA (Clinical Laboratory Improvement Amendments) and COLA (Commission on Laboratory Accreditation). These are U.S. state and federal accrediting agencies that oversee and monitor testing quality within the clinical laboratory industry.
Moleculera Labs is authorized to receive physician test orders from all 50 states in the U.S. Prescribers in New York may order the Cunningham Panel™, however at this time, patients in New York must have their blood specimen drawn at a facility outside of New York state. (There may be cases in which a patient can have a New York facility perform the blood draw but that facility would need to request and receive an approved waiver directly from the NY State Department of Health.)
Canadian prescribers can order the Cunningham Panel™ for their patients by contacting Moleculera Labs directly at 1-405-239-5250 or through our Contact Us page.
For prescribers outside the US and Canada, we have two partner laboratories that refer specimens to us: Academy of Nutritional Medicine (AONM)/Armin Labs in the UK and Statens Serum Institut in Denmark.